Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing treatments for serious eye diseases with the aim of restoring and preserving vision. Founded in 2011 and headquartered in Alpharetta, Georgia, the company specializes in a proprietary ocular microinjection platform that allows for targeted delivery of therapeutic products to specific compartments of the eye. This innovative approach includes the use of the SCS Microinjector for administering therapies directly into the suprachoroidal space, enabling a non-surgical, repeatable procedure. Among its product pipeline, Clearside is developing XIPERE, a triamcinolone acetonide injectable suspension for macular edema, and CLS-AX, an axitinib for suprachoroidal injection. The company is dedicated to advancing pharmacological therapies for sight-threatening conditions by ensuring precise and effective treatment delivery.